What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.
Ontology highlight
ABSTRACT: Uterine serous carcinoma accounts for 3-10% of endometrial cancers, but it is the most lethal histopathological subtype. The molecular characterization of endometrial carcinomas has allowed novel therapeutic approaches for these patients. We undertook a retrospective analysis of patients with uterine serous carcinomas treated in our hospital within the last two decades to identify possible changes in their management. The patients and their characteristics were evenly distributed across the two decades. Treatment modalities did not change significantly throughout this period. After adjuvant treatment, patients' median disease-free survival was 42.07 months (95% CI: 20.28-63.85), and it did not differ significantly between the two decades (p = 0.059). The median overall survival was
SUBMITTER: Liontos M
PROVIDER: S-EPMC8628752 | biostudies-literature | 2021 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA